From FDA Approval to Bankruptcy: The Cautionary Tale of Sequana Medical

GHENT, Belgium – June 26, 2026 – In a stunning reversal of fortune, Ghent-based Sequana Medical NV announced today that its board has filed for bankruptcy. The move shutters a company that, just 18 months ago, celebrated a landmark US Food and Drug Administration (FDA) approval for its innovative medical device. The collapse serves as a stark reminder that in the high-stakes world of medical technology, clinical success is no guarantee of corporate survival.

Sequana Medical, once a beacon of Belgian biotech, now finds itself a casualty of the very system it sought to innovate within. The company’s story is not just one of a failed balance sheet, but a cautionary tale about the perilous journey from invention to market, and what happens when the money runs out just as a product begins to prove its worth.

A Lifeline Cut Short

At the heart of Sequana Medical’s promise was the alfapump®, a fully implantable, battery-powered device designed to manage drug-resistant fluid overload, or ascites, in patients with severe liver disease. For these individuals, the only alternative was often frequent, painful, and costly hospital procedures to drain the fluid. The alfapump offered a revolutionary alternative, automatically pumping fluid from the abdomen to the bladder, allowing patients to regain a semblance of normal life. With over 1,000 devices already implanted worldwide, its impact was tangible.

The company appeared to be on a clear path to success. After securing a CE mark in Europe more than a decade ago, it achieved the holy grail for any medical device company: FDA Premarket Approval in December 2024. This was the culmination of the successful POSEIDON pivotal study, which proved the device’s safety and efficacy. The momentum seemed unstoppable. US commercialization began in the third quarter of 2025, targeting 90 specialized liver transplant centers. This was followed by another major win: a New Technology Add-on Payment (NTAP) from the US Centers for Medicare & Medicaid Services, providing crucial additional reimbursement to hospitals and removing a significant barrier to adoption.

Yet, behind these public victories, a financial crisis was brewing. The very process of achieving these milestones—rigorous clinical trials, complex regulatory navigation, and building a commercial sales force—requires a prodigious amount of capital.

The Unraveling of a Balance Sheet

The end came swiftly, but the signs of distress were visible for months. On April 28, the company announced a comprehensive review of its financial options, sending a clear signal of trouble. Trading of its stock on the Euronext Brussels exchange was suspended. Despite what the board called “extensive efforts and engagement with several stakeholders,” no viable financing solution or strategic buyer emerged.

Looking back, the company’s financial history reveals a story of perpetually chasing capital. A financing package of €24 million secured in March 2025 was intended to extend its cash runway, but it proved insufficient. Financial filings from mid-2025 showed a company with a net income loss of over $56 million and total debt approaching $50 million, against minimal revenue as it was still in the early stages of its US launch. Sequana Medical was caught in the classic medtech “valley of death”—the treacherous period after a product is approved but before sales revenue is sufficient to cover massive operational costs.

Each funding round—in 2020, 2021, 2022, 2023, and 2025—bought the company more time but was not enough to get it to self-sufficiency. The final press release confirmed the stark reality: “The Company has therefore determined that it will no longer be in a position to meet its obligations as they fall due.”

The Human and Clinical Fallout

Beyond the corporate wreckage, the bankruptcy leaves a trail of human and clinical consequences. The immediate future for Sequana Medical’s employees in Ghent and elsewhere is one of profound uncertainty, as they await word from court-appointed trustees. The collapse represents not just lost jobs, but the dispersal of a highly specialized team with unique expertise in a complex field of medicine.

More poignantly, the bankruptcy casts a shadow over patients. For those who could have benefited from the alfapump, a promising treatment option has been abruptly pulled from the market. The fate of the company's other major project, the DSR® (Direct Sodium Removal) therapy for diuretic-resistant heart failure, is even more definitive. Promising early results from its MOJAVE clinical study offered hope for a massive patient population, but the start of the next critical phase of the trial was contingent on securing new financing. That hope is now extinguished, representing a tangible loss for future medical progress.

A Systemic Warning for European Innovation

It is tempting to view Sequana Medical’s failure as an isolated case of a company that couldn't manage its finances. But to do so would be to miss the larger, more troubling picture. Its collapse is a symptom of a systemic weakness in the European innovation ecosystem, particularly in the life sciences.

Belgium, like much of Europe, is lauded for its world-class research and academic prowess. However, it struggles to translate that scientific excellence into globally competitive, scaled-up companies. Recent data shows a precipitous drop of nearly 50% in Belgian tech funding in the first half of 2025, with a notable pullback in the crucial growth and late-stage funding that companies like Sequana Medical desperately need to cross the commercialization valley. The EU’s own proposed Biotech Act is an admission that the continent is falling behind in creating an environment where high-potential life science firms can thrive.

Sequana Medical did what it was supposed to do: it developed a novel technology, proved its clinical value through rigorous science, and navigated the world’s most demanding regulatory body. Its failure suggests that the financial architecture designed to support such ventures is cracking under the strain. For every company that successfully makes the leap, many others, even those with validated and life-changing products, are falling into the funding chasm. The demise of Sequana Medical is not just a loss for its investors and employees; it is a warning that without a more robust and risk-tolerant funding infrastructure, Europe’s most promising innovations may continue to die on the vine.